NanoViricides is trading 5.37% up now at $1.27, apparently driven by biotech-sector momentum rather than a company-specific catalyst.
- No newly identified company-specific announcement was found on September 2, 2026.
- Investor relations lists July 14, 2026, as its latest displayed update, concerning Phase 2 Ebola trial approval.
- Biotech is up 2.75%, supported by patent-driven gains elsewhere and broader positive industry sentiment.